FDA boosts ELITE Pharma

OTC:ELTP   Elite Pharmaceuticals, Inc
NORTHVALE, NJ / ACCESSWIRE / September 12, 2019 / Elite Pharmaceuticals, Inc. ("Elite" or the “Company") ( ELTP ) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it received approval from the US Food and Drug Administration (FDA) for an Abbreviated New Drug Application (ANDA) for a generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/15mg, 300mg/30mg, and 300mg/60mg tablets.

Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications (ANDA) and New Drug Applications ( NDA ) segments. The ANDA segment includes generic pharmaceuticals. The NDA segment comprises the branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ